An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Participant has completed a prior study with PGN-EDODM1
Locations
Other Locations
Canada
Ottawa Hospital Research Institute
RECRUITING
Ottawa
CIUSSS du Saguenay-Lac-Saint-Jean
RECRUITING
Saguenay
Contact Information
Primary
PepGen Patient Advocacy
clinicaltrials@pepgen.com
781-797-0979
Time Frame
Start Date: 2025-12-23
Estimated Completion Date: 2029-01
Participants
Target number of participants: 48
Treatments
Experimental: PGN-EDODM1
Participants will receive doses of PGN-EDODM1 once every 4 weeks (Q4W)
Related Therapeutic Areas
Sponsors
Leads: PepGen Inc